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Current approach to transfemoral  
aortic valve replacement
Aktualne postępowanie podczas TAVI z dostępu przezudowego
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A b s t r a c t
We present a case of a 73 year-old male with severe aortic stenosis and high perioperative risk who was considered as a can-
didate for percutaneous valve treatment. After precise clinical assessment, the subject underwent successful transfemoral aortic 
valve replacement with a 29 mm device in analgosedation.
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CASE REPORT
The patient was a 73 year-old male with severe symptomatic 
aortic stenosis and symptoms of chronic heart failure (class III 
according to the New York Heart Association functional clas-
sification). The presence of several comorbidities including 
arterial hypertension, severe chronic obstructive pulmonary 
disease requiring long-term use of bronchodilators and ster-
oids, and pulmonary hypertension, contributed to the logistic 
Euroscore I of 13% and Society of Thoracic Surgeons score of 
3%. An echocardiographic assessment revealed a preserved 
left ventricular ejection fraction of 60%; mild hypertrophy of 
the ventricle walls; tricuspid, severely calcified aortic valve 
with valvular gradient 86/54 mm Hg and aortic valve area of 
0.7 cm2. Systolic pressure in the right ventricle was estimated 
at 60 mm Hg. In transoesophageal echocardiogram, the aortic 
annulus diameter was 26 mm. Coronary angiography showed 
a significant stenosis in the mid portion of the left anterior 
descending artery which was successfully treated with two 
bare-metal stents (4.0 × 13 mm and 3.5 × 14 mm) through 
the radial approach. The distance from the aortic annulus to 
the ostium of the left main coronary artery was estimated at 
12 mm. Angiography of iliac and lower limb arteries revealed 
a diameter of both right and left common femoral artery of 
9 mm. The subject was discussed at a Heart Team meeting 
and scheduled for transcatheter aortic-valve implantation 
(TAVI) with recommendation for femoral access and use of 
29 mm Edwards Sapien XT prosthesis (Edwards Lifesciences, 
Irvine, CA, USA).
A TAVI procedure was performed in analgosedation (sulfen-
tanil and propofol intravenous infusion) and under transthoracic 
echocardiography control. A temporary pacemaker designed for 
rapid pacing was inserted at right subclavian vein access. A diag-
nostic 6 French pigtail catheter was introduced to the ascending 
aorta through the right radial artery for intraprocedural imag-
ing purposes.  The right common femoral artery was properly 
punctured for index procedure. The calcified aortic valve was 
crossed with the support of a 6 French Amplatz left 1.0 diagnostic 
catheter. The wire was exchanged for a superstiff one. A 20 F 
expandable sheath was inserted. Balloon aortic valvuloplasty 
was performed using a 12 French 25 × 40 mm balloon under 
pacing at 180 bpm. Afterwards, a successful implantation of 
a 29 mm Edwards-Sapien XT valve under pacing at 180 bpm was 
performed (Fig. 1). The duration of the procedure was 120 min. 
with 0.9 mGy of radiation. The post-procedural transthoracic 
echocardiogram showed a gradient of 14/8 mm Hg with trivial 
aortic regurgitation and no paravalvular leaks.
DISCUSSION
The learning objective of the presented case is to show 
the possibility of a minimally invasive approach for TAVI in 
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a high-risk subject. The patient was managed with analgose-
dation only to avoid the stress related to general anaesthesia. 
There was no need for intubation and mechanical ventilation 
during the procedure. A temporary pacemaker was inserted 
through the subclavian vein and was kept for 72 h, as is 
routine in our centre, so the risk of haematoma and threats 
resulting from immobility were reduced. By puncturing of the 
radial artery for diagnostic purposes during the procedure, 
a bleeding complication related to potential femoral access 
was also avoided. Moreover, in mid-May 2012 a new 29 mm 
device (Fig. 2), covering the aortic annulus diameter between 
25–27 mm, was released by Edwards for general clinical use. 
The minimal required diameter of common femoral artery is 
7.5 mm. The balloon used for balloon aortic valvuloplasty is 
25 × 40 mm. The height of the device is 19.1 mm, so the 
distance between aortic annulus and coronary ostia is crucial.
Conflict of interest: none declared
References 
1. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcathe­
ter implantation of an aortic valve prosthesis for calcific aortic 
stenosis: first human case description. Circulation, 2002; 106: 
3006–3008.
2. Vahanian A, Alfieri O, Al­Attar N et al. European Association 
of Cardio­Thoracic Surgery; European Society of Cardiology; 
European Association of Percutaneous Cardiovascular Interven­
tions. Transcatheter valve implantation for patients with aortic 
stenosis: a position statement from the European Association of 
Cardio­Thoracic Surgery (EACTS) and the European Society of 
Cardiology (ESC), in collaboration with the European Associa­
tion of Percutaneous Cardiovascular Interventions (EAPCI). Eur 
Heart J, 2008; 29: 1463–1470.
3. Leon MB, Smith CR, Mack M et al. Transcatheter aortic­valve 
implantation for aortic stenosis in patients who cannot undergo 
surgery. N Engl J Med, 2010; 363: 1597–1607.
4. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgi­
cal aortic­valve replacement in high­risk patients. N Engl J Med, 
2011; 364: 2187–2198. 
Figure 1. Intraprocedural images: balloon aortic valvuloplasty with 25 × 40 mm balloon and 29 mm Edwards Sapien XT pros-
thesis after successful deployment
Figure 2. New 29 mm device set; A. Balloon dedicated to balloon aortic valvuloplasty; B. Delivery system of the 29 mm;  
C. Edwards Sapien XT 29 mm
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